VERU

VERU INC. (The Female Health Company) - 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for The Female Health Company (VERU Inc.) for the period ended December 31, 2010. The Company manufactures, markets, and distributes the FC2 female condom, the only FDA-approved product under a woman's control providing dual protection against unintended pregnancy and sexually transmitted infections (STIs), including HIV/AIDS. The Company completed the transition from its first-generation product (FC1) to FC2 in October 2009. FC2 is sold in 114 countries, primarily to public health sector organizations and governments.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net revenues decreased 33% ($1.84 million) due to a 36% decrease in unit volume. Management attributes this to the timing of large orders from public health sector purchasers, specifically delays in two multi-million unit orders, rather than a fundamental change in demand.
• Profitability Turnaround: The Company reported a net income of $386,668 compared to a net loss of $698,351 in the prior year. This improvement is primarily driven by the absence of $1.9 million in one-time restructuring costs incurred in Q1 2010 related to the closure of the U.K. manufacturing facility.
• Operating Expenses: Total operating expenses decreased by $2.24 million ($58.6%) year-over-year. Selling, general, and administrative (SG&A) expenses dropped 16% due to lower incentive compensation, reduced marketing, and lower rent. Restructuring costs were $0 in the current period versus $1.9 million in the prior period.
• Cash Flow: Net cash provided by operating activities increased significantly to $2.1 million from $0.4 million, aided by a decrease in accounts receivable ($2.1 million reduction) and strong collections.
• Dividends: The Company paid approximately $1.4 million in cash dividends during the quarter, a new cash outflow not present in the prior year.

Guidance, Outlook, and Risks

• Outlook: Management does not believe the revenue delay reflects a fundamental change in business or demand. They anticipate pending orders will be received, though timing is unpredictable due to bureaucracy and political factors in public health procurement.
• Dividend Policy: The Board declared a quarterly cash dividend of $0.05 per share on January 14, 2011, payable in February 2011. Future dividends are at the Board's discretion and depend on cash flows.
• Liquidity: The Company has a $2 million line of credit with Heartland Bank (two $1 million revolving notes), with no amounts outstanding as of December 31, 2010. The Company believes its cash position is adequate for the next 12 months.
• Risks:
  • Single Product Reliance: The Company relies almost entirely on the FC2 female condom for revenue.
  • Customer Concentration: A limited number of large public health sector customers account for a significant portion of revenue; delays in their procurement processes cause significant quarterly volatility.
  • Regulatory: FC2 is a Class III medical device subject to FDA regulation; failure to comply could result in withdrawal of approval.
  • Competition: While FC2 is the only FDA-approved female condom, male condoms are cheaper and more widely recognized. Competitors with greater resources may develop competing products.

Key Facts for Investor Verification

• Order Timing: Verify the status of the delayed multi-million unit orders from Brazil and other public health agencies mentioned as the cause for the revenue decline.
• Dividend Sustainability: Assess whether the Company's cash flow from operations ($2.1M) can consistently support the quarterly dividend payments (~$1.4M per quarter) alongside working capital needs.
• Inventory Levels: Inventory increased to $2.84 million (up from $2.19 million) while sales volume dropped; verify if this indicates a buildup of unsold goods or strategic stockpiling for anticipated large orders.
• Restructuring Completion: Confirm that the $1.9 million restructuring charge from the prior year is fully resolved and no further exit costs are expected from the U.K. facility closure.
• Debt Covenants: Note that the credit facility requires a minimum of $1 million in available cash and a 1:1 liabilities-to-equity ratio to maintain dividend and share repurchase privileges.